The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
11-Jan-24
Undisclosed
Target:
ElectraMeccanica
Acquiror:
Xos
Advising ElectraMeccanica on its all-stock merger with Xos, a leading manufacturer of battery electric commercial vehicles
18-Sep-23
Pending
Undisclosed
Target:
Central nervous system (CNS) portfolio from Sanofi
Acquiror:
Pharmanovia
Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company
01-Jun-23
$90.4 million
Target:
PCAS Canada Inc.
Acquiror:
DIC Corporation
Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens
05-Apr-23
Pending
$185 million
Target:
Calibre Group’s QuadR Business
Acquiror:
WSP Global Inc.
Advising Calibre Group, an Australian diversified engineering group, on the sale of its Calibre QuadR business to WSP Global Inc., a leading global engineering and professional services firm
07-Nov-22
Undisclosed
Target:
Industrias Dolz
Acquiror:
Litens Automotive Group
Advised Realza Capital Partners, a leading Spanish private equity firm, on the disposal of Industrias Dolz, a leading global player in the manufacturing and distribution of water pumps for the independent automotive market (IAM).
11-Oct-22
Pending
$7.9 billion
Target:
Westinghouse Electric Company
Acquiror:
Brookfield Renewable Partners and Cameco
Advising the Independent Committee of Brookfield Renewable Partners, the flagship listed renewable power company of Brookfield Asset Management, in consortium with Cameco and other institutional partners, on the acquisition of Westinghouse Electric Company, one of the world’s largest nuclear services businesses, from Brookfield Business Partners
18-Mar-22
Pending
~$190 million
Target:
Veritiv Canada
Acquiror:
Imperial Dade
Advising Veritiv Corporation, a leading North American distributor of packaging, facility solutions, print and publishing products and services, on the sale of Veritiv Canada, Inc. to Imperial Dade, a portfolio company of Bain Capital
08-Sep-21
Undisclosed
Target:
Hydrogen Technology & Energy Corporation (HTEC)
Acquiror:
I Squared Capital
Advising I Squared Capital, an independent global infrastructure investment manager, on its acquisition of a 35% equity interest in HTEC, a privately-held leader in the hydrogen energy transition
03-Aug-21
Undisclosed
Target:
American Hotel Register Company, Inc.’s North American Assets
Acquiror:
Consolidated Hospitality Supplies, LLC
Advised American Hotel Register Company, Inc. on the sale of its North American assets to Consolidated Hospitality Supplies, LLC
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
19-Dec-19
$770 million
Target:
Wireless Infrastructure Group Limited
Acquiror:
Brookfield Asset Management
Advised 3i Infrastructure plc on the sale of Wireless Infrastructure Group Limited, a leading independent telecommunications infrastructure provider focusing on mobile towers and indoor connectivity
19-Nov-19
$NA
Target:
Controlling ownership interest in CrossAmerica Partners LP
Acquiror:
Investment entities controlled by Joe Topper
Advised Alimentation Couche-Tard Inc., a multinational convenience store operator, on the strategic review and subsequent sale of its controlling ownership (which included 100% of the general partner interest, 100% of the incentive distribution rights and ~7.5mm limited partner units) in CrossAmerica Partners LP (NYSE: CAPL), a leading wholesale fuels distributor and convenience store lessor in the United States
10-Jul-19
$NA
Target:
ICC Brazil
Acquiror:
Lallemand
Advised ICC Brazil, the leader in animal health and nutrition ingredients derived from yeast in Brazil, on establishing a long term strategic partnership with Lallemand, a global leader in the development, production and marketing of yeast, bacteria and specialty ingredients
17-Jun-19
$80 million
Target:
Renewi Canada
Acquiror:
Convent Capital
Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
30-Jul-18
$435 million
Target:
Berger Group Holdings, Inc.
Acquiror:
WSP Global Inc.
Advised Berger Group Holdings, Inc. (“Louis Berger”), a leading international professional services engineering firm, on its sale to WSP Global Inc.
29-May-18
$3.5 billion
Target:
Trans Mountain Pipeline system, Trans Mountain Expansion Project and related pipeline and terminal assets
Acquiror:
Government of Canada
Advised the Government of Canada on the acquisition of the Trans Mountain Pipeline system, the Trans Mountain Expansion Project and related pipeline and terminal assets from Kinder Morgan Canada Limited
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
26-Apr-18
$NA
Target:
IslaLink
Acquiror:
Fiera Infrastructure
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
24-Nov-16
$NA
Target:
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Rivopharm SA
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
23-Nov-16
$NA
Target:
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Acquiror:
Arrow Generiques SAS
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
14-Jun-15
$912 million
Target:
Niska Gas Storage Partners
Acquiror:
Brookfield Infrastructure Group
Advised the Conflicts Committee of the Board of Directors of Niska and provided a fairness opinion on its sale to Brookfield
08-Jun-15
$45 million
Target:
Aralez Pharmaceuticals Inc.
Acquiror:
QLT Inc.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
21-Dec-12
$75 million
Target:
Australian Portable Buildings
Acquiror:
Black Diamond Group Limited and WEQ Britco LP
Advised CHAMP Ventures on the sale of its portfolio company Australian Portable Buildings, a leading Australian manufacturer of customized modular buildings, to a consortium comprising Black Diamond Group and WEQ Britco
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
20-Jun-11
$2.0 billion
Target:
Capital Power Income L.P.
Acquiror:
Atlantic Power Corporation
Advised Capital Power Income L.P., a Canadian power trust with a portfolio of 20 power generation assets located in Canada and the United States (total net generating capacity of 1,400 MW), on its sale to Atlantic Power Corporation
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
30-Jun-10
$820 million
Target:
Trident Resources Corporation
Advised Chilton Investment Company on Trident’s financial restructuring and emergence from CCAA / Chapter 11 bankruptcy protection including the negotiation of a new equity investment
07-Jun-09
$1.6 billion
Target:
EPCOR Power L.P.
Advised the Independent Committee of the Board of Directors of EPCOR Power L.P., an Alberta-based power trust, on approval of the transfer of its GP interest and 30.6% LP interest from EPCOR Utilities to a newly formed company, Capital Power Corporation
31-Jul-08
$10.3 billion
Target:
TransAlta Corporation
Acquiror:
LS Power Equity Partners / Global Infrastructure Partners
Advised TransAlta Corporation, a power generation and wholesale marketing company, on an unsolicited offer from LS Power Equity Partners / Global Infrastructure Partners
03-May-07
$8.5 billion
Target:
IPSCO Inc.
Acquiror:
SSAB Svenskt Stål AB
Acted as lead financial advisor to SSAB Svenskt Stål AB on its acquisition of IPSCO Inc., a leading Canadian producer of energy tubulars and steel plate in North America with an annual steel making capacity of 4.3 million tons
16-Jul-01
$982 million
Target:
Sterling Chemicals
Advised Sterling Chemicals in connection with its Chapter 11 proceedings